Marina Garassino comments on checkpoint inhibition in lung cancer patients with oncogenic drivers, highlights novel developing therapies in EGFR-mutant NSCLC patients with resistance to TKIs, summarizes the most relevant findings presented at ESMO 2022 in terms of the management of patients with previously untreated, metastatic non-squamous and squamous NSCLC without EGFR/ALK alterations as well as patients with extensive-stage small-cell lung cancer; and finally discusses how artificial intelligence can be used to predict the efficacy of immunotherapy in lung cancer patients.

Here is the full ESMO 2022 Lung Cancer report.